Intrinsic value of Five Prime Therapeutics - FPRX

Previous Close

$16.97

  Intrinsic Value

$2.37

stock screener

  Rating & Target

str. sell

-86%

Previous close

$16.97

 
Intrinsic value

$2.37

 
Up/down potential

-86%

 
Rating

str. sell

We calculate the intrinsic value of FPRX stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2017), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046
   2047

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  28.70
  26.33
  24.20
  22.28
  20.55
  18.99
  17.60
  16.34
  15.20
  14.18
  13.26
  12.44
  11.69
  11.02
  10.42
  9.88
  9.39
  8.95
  8.56
  8.20
  7.88
  7.59
  7.33
  7.10
  6.89
  6.70
  6.53
  6.38
  6.24
  6.12
Revenue, $m
  51
  65
  81
  99
  119
  142
  167
  194
  223
  255
  289
  325
  363
  403
  445
  489
  534
  582
  632
  684
  738
  794
  852
  913
  975
  1,041
  1,109
  1,179
  1,253
  1,330
Variable operating expenses, $m
  218
  275
  341
  417
  503
  599
  704
  819
  944
  1,078
  1,221
  1,372
  1,533
  1,702
  1,879
  2,065
  2,259
  2,461
  2,672
  2,891
  3,119
  3,355
  3,602
  3,857
  4,123
  4,399
  4,687
  4,986
  5,297
  5,621
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  218
  275
  341
  417
  503
  599
  704
  819
  944
  1,078
  1,221
  1,372
  1,533
  1,702
  1,879
  2,065
  2,259
  2,461
  2,672
  2,891
  3,119
  3,355
  3,602
  3,857
  4,123
  4,399
  4,687
  4,986
  5,297
  5,621
Operating income, $m
  -166
  -210
  -261
  -319
  -384
  -457
  -538
  -625
  -721
  -823
  -932
  -1,048
  -1,170
  -1,299
  -1,435
  -1,576
  -1,724
  -1,879
  -2,040
  -2,207
  -2,381
  -2,562
  -2,750
  -2,945
  -3,148
  -3,359
  -3,578
  -3,806
  -4,044
  -4,291
EBITDA, $m
  -164
  -207
  -257
  -314
  -379
  -451
  -530
  -616
  -710
  -811
  -918
  -1,033
  -1,153
  -1,280
  -1,414
  -1,554
  -1,699
  -1,852
  -2,010
  -2,175
  -2,346
  -2,524
  -2,710
  -2,902
  -3,102
  -3,310
  -3,526
  -3,751
  -3,985
  -4,229
Interest expense (income), $m
  0
  0
  1
  3
  4
  6
  9
  11
  14
  17
  20
  23
  27
  31
  35
  39
  44
  48
  53
  58
  64
  69
  75
  81
  88
  94
  101
  108
  115
  123
  131
Earnings before tax, $m
  -166
  -211
  -263
  -323
  -391
  -466
  -549
  -639
  -737
  -843
  -955
  -1,075
  -1,201
  -1,334
  -1,474
  -1,620
  -1,773
  -1,932
  -2,098
  -2,271
  -2,450
  -2,637
  -2,831
  -3,032
  -3,242
  -3,459
  -3,686
  -3,921
  -4,166
  -4,422
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -166
  -211
  -263
  -323
  -391
  -466
  -549
  -639
  -737
  -843
  -955
  -1,075
  -1,201
  -1,334
  -1,474
  -1,620
  -1,773
  -1,932
  -2,098
  -2,271
  -2,450
  -2,637
  -2,831
  -3,032
  -3,242
  -3,459
  -3,686
  -3,921
  -4,166
  -4,422

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  131
  166
  206
  252
  304
  361
  425
  494
  570
  650
  737
  828
  925
  1,027
  1,134
  1,246
  1,363
  1,485
  1,612
  1,745
  1,882
  2,025
  2,174
  2,328
  2,488
  2,655
  2,828
  3,009
  3,197
  3,392
Adjusted assets (=assets-cash), $m
  131
  166
  206
  252
  304
  361
  425
  494
  570
  650
  737
  828
  925
  1,027
  1,134
  1,246
  1,363
  1,485
  1,612
  1,745
  1,882
  2,025
  2,174
  2,328
  2,488
  2,655
  2,828
  3,009
  3,197
  3,392
Revenue / Adjusted assets
  0.389
  0.392
  0.393
  0.393
  0.391
  0.393
  0.393
  0.393
  0.391
  0.392
  0.392
  0.393
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
  0.392
Average production assets, $m
  24
  30
  38
  46
  56
  66
  78
  91
  104
  119
  135
  152
  170
  188
  208
  229
  250
  272
  296
  320
  345
  372
  399
  427
  456
  487
  519
  552
  586
  622
Working capital, $m
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -11
  -13
  -15
  -16
  -19
  -21
  -23
  -25
  -28
  -30
  -33
  -36
  -39
  -42
  -45
  -49
  -52
  -56
  -59
  -63
  -67
  -71
  -76
Total debt, $m
  24
  51
  82
  118
  158
  204
  253
  308
  366
  430
  497
  569
  644
  724
  808
  895
  987
  1,082
  1,182
  1,285
  1,393
  1,505
  1,621
  1,741
  1,867
  1,997
  2,133
  2,274
  2,421
  2,574
Total liabilities, $m
  103
  130
  161
  197
  238
  283
  332
  387
  445
  509
  576
  648
  723
  803
  887
  975
  1,066
  1,161
  1,261
  1,364
  1,472
  1,584
  1,700
  1,820
  1,946
  2,076
  2,212
  2,353
  2,500
  2,653
Total equity, $m
  29
  36
  45
  55
  66
  79
  93
  108
  124
  142
  161
  181
  202
  224
  247
  272
  297
  324
  351
  380
  410
  441
  474
  507
  542
  579
  617
  656
  697
  739
Total liabilities and equity, $m
  132
  166
  206
  252
  304
  362
  425
  495
  569
  651
  737
  829
  925
  1,027
  1,134
  1,247
  1,363
  1,485
  1,612
  1,744
  1,882
  2,025
  2,174
  2,327
  2,488
  2,655
  2,829
  3,009
  3,197
  3,392
Debt-to-equity ratio
  0.830
  1.400
  1.830
  2.150
  2.390
  2.580
  2.730
  2.850
  2.950
  3.030
  3.090
  3.150
  3.200
  3.230
  3.270
  3.300
  3.320
  3.340
  3.360
  3.380
  3.390
  3.410
  3.420
  3.430
  3.440
  3.450
  3.460
  3.470
  3.470
  3.480
Adjusted equity ratio
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218
  0.218

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -166
  -211
  -263
  -323
  -391
  -466
  -549
  -639
  -737
  -843
  -955
  -1,075
  -1,201
  -1,334
  -1,474
  -1,620
  -1,773
  -1,932
  -2,098
  -2,271
  -2,450
  -2,637
  -2,831
  -3,032
  -3,242
  -3,459
  -3,686
  -3,921
  -4,166
  -4,422
Depreciation, amort., depletion, $m
  2
  3
  4
  5
  6
  7
  8
  9
  10
  12
  14
  15
  17
  19
  21
  23
  25
  27
  30
  32
  35
  37
  40
  43
  46
  49
  52
  55
  59
  62
Funds from operations, $m
  -164
  -208
  -260
  -319
  -385
  -459
  -541
  -630
  -727
  -831
  -942
  -1,059
  -1,184
  -1,315
  -1,453
  -1,597
  -1,748
  -1,905
  -2,069
  -2,239
  -2,416
  -2,600
  -2,791
  -2,990
  -3,196
  -3,411
  -3,634
  -3,866
  -4,108
  -4,359
Change in working capital, $m
  -1
  -1
  -1
  -1
  -1
  -1
  -1
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -2
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -3
  -4
  -4
  -4
  -4
  -4
  -4
Cash from operations, $m
  -163
  -207
  -259
  -317
  -384
  -458
  -539
  -629
  -725
  -829
  -940
  -1,057
  -1,182
  -1,313
  -1,451
  -1,595
  -1,745
  -1,902
  -2,066
  -2,236
  -2,413
  -2,597
  -2,788
  -2,986
  -3,192
  -3,407
  -3,630
  -3,862
  -4,104
  -4,355
Maintenance CAPEX, $m
  -2
  -2
  -3
  -4
  -5
  -6
  -7
  -8
  -9
  -10
  -12
  -14
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -30
  -32
  -35
  -37
  -40
  -43
  -46
  -49
  -52
  -55
  -59
New CAPEX, $m
  -6
  -6
  -7
  -8
  -9
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -20
  -21
  -21
  -22
  -23
  -24
  -25
  -26
  -27
  -28
  -29
  -31
  -32
  -33
  -34
  -36
Cash from investing activities, $m
  -8
  -8
  -10
  -12
  -14
  -17
  -19
  -21
  -23
  -25
  -28
  -31
  -33
  -36
  -39
  -42
  -44
  -47
  -50
  -54
  -57
  -61
  -64
  -68
  -72
  -77
  -81
  -85
  -89
  -95
Free cash flow, $m
  -171
  -216
  -269
  -330
  -398
  -474
  -558
  -649
  -748
  -854
  -967
  -1,088
  -1,215
  -1,349
  -1,489
  -1,636
  -1,790
  -1,950
  -2,116
  -2,290
  -2,470
  -2,657
  -2,852
  -3,054
  -3,265
  -3,483
  -3,711
  -3,947
  -4,193
  -4,450
Issuance/(repayment) of debt, $m
  24
  27
  31
  36
  40
  45
  50
  54
  59
  63
  67
  72
  76
  80
  84
  88
  92
  95
  99
  103
  108
  112
  116
  121
  125
  130
  136
  141
  147
  153
Issuance/(repurchase) of shares, $m
  173
  219
  272
  333
  402
  478
  562
  654
  754
  860
  974
  1,095
  1,222
  1,356
  1,497
  1,644
  1,798
  1,959
  2,126
  2,300
  2,480
  2,668
  2,863
  3,066
  3,277
  3,496
  3,724
  3,961
  4,207
  4,464
Cash from financing (excl. dividends), $m  
  197
  246
  303
  369
  442
  523
  612
  708
  813
  923
  1,041
  1,167
  1,298
  1,436
  1,581
  1,732
  1,890
  2,054
  2,225
  2,403
  2,588
  2,780
  2,979
  3,187
  3,402
  3,626
  3,860
  4,102
  4,354
  4,617
Total cash flow (excl. dividends), $m
  26
  30
  34
  39
  44
  49
  55
  60
  64
  69
  74
  79
  83
  87
  92
  96
  100
  105
  109
  113
  118
  123
  127
  132
  138
  143
  149
  155
  161
  168
Retained Cash Flow (-), $m
  -173
  -219
  -272
  -333
  -402
  -478
  -562
  -654
  -754
  -860
  -974
  -1,095
  -1,222
  -1,356
  -1,497
  -1,644
  -1,798
  -1,959
  -2,126
  -2,300
  -2,480
  -2,668
  -2,863
  -3,066
  -3,277
  -3,496
  -3,724
  -3,961
  -4,207
  -4,464
Prev. year cash balance distribution, $m
  243
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  10
  13
  16
  20
  25
  30
  35
  42
  48
  56
  64
  72
  81
  91
  101
  111
  122
  134
  146
  158
  171
  184
  198
  213
  228
  244
  260
  277
  295
  313
Cash available for distribution, $m
  96
  -189
  -238
  -294
  -357
  -429
  -508
  -595
  -689
  -791
  -900
  -1,016
  -1,139
  -1,269
  -1,405
  -1,548
  -1,698
  -1,854
  -2,017
  -2,186
  -2,362
  -2,545
  -2,736
  -2,934
  -3,139
  -3,353
  -3,575
  -3,806
  -4,046
  -4,297
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  92
  -173
  -207
  -242
  -277
  -311
  -343
  -372
  -396
  -415
  -427
  -434
  -433
  -426
  -413
  -393
  -369
  -341
  -311
  -278
  -244
  -211
  -179
  -149
  -122
  -98
  -77
  -59
  -44
  -32
Current shareholders' claim on cash, %
  18.4
  3.5
  0.7
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

FINANCIAL RATIOS  of  Five Prime Therapeutics (FPRX)

Valuation Ratios
P/E Ratio -7.1
Price to Sales 15.1
Price to Book 1.2
Price to Tangible Book
Price to Cash Flow -5.8
Price to Free Cash Flow -5.6
Growth Rates
Sales Growth Rate -91.8%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 50%
Cap. Spend. - 3 Yr. Gr. Rate 24.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets -13.3%
Ret/ On Assets - 3 Yr. Avg. 8.9%
Return On Total Capital -16%
Ret/ On T. Cap. - 3 Yr. Avg. 9.6%
Return On Equity -16%
Return On Equity - 3 Yr. Avg. 9.6%
Asset Turnover 0.1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -306.5%
EBITDA Margin - 3 Yr. Avg. -138.2%
Operating Margin -319.4%
Oper. Margin - 3 Yr. Avg. -147.9%
Pre-Tax Margin -312.9%
Pre-Tax Margin - 3 Yr. Avg. -144%
Net Profit Margin -212.9%
Net Profit Margin - 3 Yr. Avg. -114%
Effective Tax Rate 32%
Eff/ Tax Rate - 3 Yr. Avg. 15%
Payout Ratio 0%

FPRX stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the FPRX stock intrinsic value calculation we used $40 million for the last fiscal year's total revenue generated by Five Prime Therapeutics. The default revenue input number comes from 2017 income statement of Five Prime Therapeutics. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our FPRX stock valuation model: a) initial revenue growth rate of 28.7% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for FPRX is calculated based on our internal credit rating of Five Prime Therapeutics, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Five Prime Therapeutics.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of FPRX stock the variable cost ratio is equal to 422.7%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for FPRX stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Five Prime Therapeutics.

Corporate tax rate of 27% is the nominal tax rate for Five Prime Therapeutics. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the FPRX stock is equal to 25%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for FPRX are equal to 46.8%.

Life of production assets of 10 years is the average useful life of capital assets used in Five Prime Therapeutics operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for FPRX is equal to -5.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $265 million for Five Prime Therapeutics - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 28 million for Five Prime Therapeutics is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Five Prime Therapeutics at the current share price and the inputted number of shares is $0.5 billion.

RELATED COMPANIES Price Int.Val. Rating
BMY Bristol-Myers 56.71 54.20  hold
BLUE bluebird bio 180.35 9.05  str.sell
PFE Pfizer 37.33 24.58  sell
GSK GlaxoSmithKlin 41.87 39.73  hold
LLY Eli Lilly 88.47 51.30  sell
MRK Merck&Co 62.52 22.92  str.sell
AMGN Amgen 190.49 91.73  sell
PIRS Pieris Pharmac 5.83 8.66  buy

COMPANY NEWS

▶ 5 Top-Ranked High-Beta Stocks to Play the Roaring Market   [Jun-07-18 11:05AM  InvestorPlace]
▶ Five Prime Therapeutics: 1Q Earnings Snapshot   [May-08-18 06:09PM  Associated Press]
▶ Five Prime to Present at 2018 ASCO Annual Meeting   [Apr-25-18 03:01PM  Business Wire]
▶ Five Prime Therapeutics Announces Executive Change   [Mar-13-18 04:05PM  Business Wire]
▶ Five Prime Therapeutics posts 4Q loss   [Feb-27-18 06:03PM  Associated Press]
▶ A Six-Pack of Biotech Bets   [Feb-22-18 06:00AM  Investopedia]
▶ High Growth Stocks To Invest In   [Feb-01-18 11:02AM  Simply Wall St.]
▶ January Growth Stock Opportunities   [Jan-01-18 11:02AM  Simply Wall St.]
▶ Why This Biotech Still Gets Hit Despite Promising Cancer Data   [Nov-13-17 04:07PM  Investor's Business Daily]
▶ Five Prime Therapeutics posts 3Q loss   [04:59PM  Associated Press]
▶ Five Prime Therapeutics posts 2Q loss   [Aug-08-17 11:59PM  Associated Press]
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.